Effektivnost' i bezopasnost' ezhenedel'nogo vvedeniya paklitaksela bol'nym metastaticheskim rakom molochnoy zhelezy: rezul'taty prospektivnogo mnogotsentrovogo klinicheskogo issledovaniya

Breast cancer is the leading cause of cancer mortality among women. The disease is often diagnosed at advanced stage. Despite recent advances in metastatic breast cancer (MBC) treatment, optimal therapy regimen is still to be determined. We have conducted this prospective multicenter trial to assess the efficacy and safety of weekly infusion of paclitaxel (Taxacad®) 80 mg/m 2 in MBC patients. The trial has included 19 MBC patients. All patients have received 24 paclitaxel infusions (3 cycles). Grade 3 adverse events (AEs) (rated according to NTICTCAE v. 2.0) were reported in 6 (31,6 %) patients (neutropenia, peripheral sensory neuropathy, AST elevation). No cases of grade 4 AEs were observed. In 1 patient grade 3 AE (peripheral sensory neuropathy) has lead to treatment discontinuation. Treatment response was assessed using RECIST criteria in 18 patients. After 3 cycles of chemotherapy partial response was achieved in 11 (57,9 %) patients, disease stabilization - in 4 (21,1 %) patients. The disease has progressed during the treatment in 4 (21,1 %) patients. Median follow-up was 8,5 (2-24) months; median time to progression was 9 (1-12) months. In conclusion, weekly paclitaxel monotherapy can be safely used in MBC patients.

breast cancer, taxanes, paclitaxel, adverse events